DOCSLIB.ORG

Output Results of CLIME (Clustering by Inferred Models of Evolution)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Output Results of CLIME (Clustering by Inferred Models of Evolution) Output results of CLIME (CLustering by Inferred Models of Evolution) Dataset: Num of genes in input gene set: 2 Total number of genes: 20834 Prediction LLR threshold: 0 The CLIME PDF output two sections: 1) Overview of Evolutionarily Conserved Modules (ECMs) Top panel shows the predefined species tree. Bottom panel shows the partition of input genes into Evolutionary Conserved Modules (ECMs), ordered by ECM strength (shown at right), and separated by horizontal lines. Each row show one gene, where the phylogenetic profile indicates presence (blue) or absence (gray) of homologs in each species (column). Gene symbols are shown at left. Gray color indicates that the gene is a paralog to a higher scoring gene within the same ECM (based on BLASTP E < 1e-3). 2) Details of each ECM and its expansion ECM+ Top panel shows the inferred evolutionary history on the predefined species tree. Branch color shows the gain event (blue) and loss events (red color, with brighter color indicating higher confidence in loss). Branches before the gain or after a loss are shown in gray. Bottom panel shows the input genes that are within the ECM (blue/white rows) as well as all genes in the expanded ECM+ (green/gray rows). The ECM+ includes genes likely to have arisen under the inferred model of evolution relative to a background model, and scored using a log likelihood ratio (LLR). PG indicates "paralog group" and are labeled alphabetically (i.e., A, B). The first gene within each paralog group is shown in black color. All other genes sharing sequence similarity (BLAST E < 1e-3) are assigned to the same PG label and displayed in gray. ECM 1 Protein D2HGDH IDH2 Overview ofEvolutionarilyConservedModules(ECMs) Prokaryotes Prokaryotes Last CommonAncestor E.cuniculi E.cuniculi E.histolytica E.histolytica E.dispar E.dispar G.lamblia G.lamblia T.vaginalis T.vaginalis T.brucei T.brucei T.cruzi T.cruzi L.infantum L.infantum L.major L.major L.braziliensis L.braziliensis T.gondii T.gondii Protists C.hominis C.hominis C.parvum C.parvum B.bovis B.bovis T.annulata T.annulata T.parva T.parva P.knowlesi P.knowlesi P.vivax P.vivax P.falciparum P.falciparum P.chabaudi P.chabaudi P.berghei P.berghei P.yoelii P.yoelii P.tetraurelia P.tetraurelia T.thermophila T.thermophila P.infestans P.infestans T.pseudonana T.pseudonana P.tricornutum P.tricornutum C.merolae C.merolae N.gruberi N.gruberi O.lucimarinus O.lucimarinus O.tauri O.tauri C.reinhardtii C.reinhardtii V.carteri V.carteri P.patens P.patens S.moellendorffii Plants S.moellendorffii S.bicolor S.bicolor Z.mays Z.mays O.sativa O.sativa B.distachyon B.distachyon A.lyrata A.lyrata A.thaliana A.thaliana L.japonicus L.japonicus M.truncatula M.truncatula V.vinifera V.vinifera P.trichocarpa P.trichocarpa R.communis R.communis T.trahens T.trahens D.discoideum D.discoideum A.macrogynus A.macrogynus S.punctatus S.punctatus M.globosa M.globosa U.maydis U.maydis C.neoformans C.neoformans P.chrysosporium P.chrysosporium S.commune S.commune C.cinerea C.cinerea L.bicolor L.bicolor S.pombe S.pombe B.fuckeliana B.fuckeliana S.sclerotiorum S.sclerotiorum F.graminearum F.graminearum M.grisea M.grisea N.crassa N.crassa P.anserina P.anserina P.chrysogenum P.chrysogenum A.clavatus A.clavatus A.fumigatus A.fumigatus N.fischeri N.fischeri A.flavus A.flavus A.oryzae A.oryzae A.niger A.niger A.nidulans Fungi A.nidulans U.reesii U.reesii C.immitis C.immitis C.posadasii C.posadasii P.nodorum P.nodorum T.melanosporum T.melanosporum Y.lipolytica Y.lipolytica P.pastoris P.pastoris C.lusitaniae C.lusitaniae D.hansenii D.hansenii M.guilliermondii M.guilliermondii S.stipitis S.stipitis L.elongisporus L.elongisporus C.tropicalis C.tropicalis C.albicans C.albicans C.dubliniensis C.dubliniensis K.lactis K.lactis A.gossypii A.gossypii K.waltii K.waltii L.thermotolerans L.thermotolerans Z.rouxii Z.rouxii V.polyspora V.polyspora C.glabrata C.glabrata S.bayanus S.bayanus S.mikatae S.mikatae S.cerevisiae S.cerevisiae S.paradoxus S.paradoxus S.arctica S.arctica C.owczarzaki C.owczarzaki M.brevicollis M.brevicollis S.rosetta S.rosetta S.mansoni S.mansoni B.malayi B.malayi C.briggsae C.briggsae C.elegans C.elegans D.pulex D.pulex A.pisum A.pisum P.humanus P.humanus A.mellifera A.mellifera N.vitripennis N.vitripennis B.mori B.mori T.castaneum T.castaneum D.melanogaster D.melanogaster D.pseudoobscura D.pseudoobscura A.gambiae A.gambiae A.aegypti A.aegypti C.quinquefasciatus Metazoa C.quinquefasciatus B.floridae B.floridae T.adhaerens T.adhaerens S.purpuratus S.purpuratus H.magnipapillata H.magnipapillata N.vectensis N.vectensis C.intestinalis C.intestinalis D.rerio D.rerio O.latipes O.latipes F.rubripes F.rubripes T.nigroviridis T.nigroviridis X.tropicalis X.tropicalis G.gallus G.gallus M.gallopavo M.gallopavo O.anatinus O.anatinus M.domestica M.domestica S.scrofa S.scrofa M.musculus M.musculus C.familiaris C.familiaris B.taurus B.taurus H.sapiens H.sapiens Strength 2.5 PG C C C C C C C C C C C C C C C C C C C C E E C C D C C B C B C C C B A Protein CYP11A1 CYP17A1 CYP4A22 CYP27C1 CYP11B1 CYP24A1 CYP21A2 CYP26A1 CYP26B1 CYP46A1 CYP3A43 CYP26C1 CYP39A1 CYP20A1 CYP4F12 D2HGDH CYP2D6 CYP3A7 CYP2C8 CYP3A5 CYP2B6 CYP8B1 CYP7B1 CYP7A1 CYP2S1 CYP4X1 CYP4V2 CYP2E1 MSMO1 SC5DL HIBCH PTGIS AGPS LDHD IDH2 1: D-2-hydroxyglutaric aciduria || Num ofECMGenes:2.Predicted100.Strength:2.5 ECM 1,Geneset"D-2-hydroxyglutaricaciduria",Page1 Prokaryotes Prokaryotes Last CommonAncestor E.cuniculi E.cuniculi E.histolytica E.histolytica E.dispar E.dispar G.lamblia G.lamblia T.vaginalis T.vaginalis T.brucei T.brucei T.cruzi T.cruzi L.infantum L.infantum L.major L.major L.braziliensis L.braziliensis T.gondii T.gondii Protists C.hominis C.hominis C.parvum C.parvum B.bovis B.bovis T.annulata T.annulata 2: Hypertension || T.parva T.parva P.knowlesi P.knowlesi P.vivax P.vivax P.falciparum P.falciparum P.chabaudi P.chabaudi P.berghei P.berghei P.yoelii P.yoelii P.tetraurelia P.tetraurelia T.thermophila T.thermophila P.infestans P.infestans T.pseudonana T.pseudonana 3: Rhizomelic chondrodysplasia punctata || P.tricornutum P.tricornutum C.merolae C.merolae N.gruberi N.gruberi O.lucimarinus O.lucimarinus O.tauri O.tauri C.reinhardtii C.reinhardtii V.carteri V.carteri P.patens P.patens S.moellendorffii Plants S.moellendorffii S.bicolor S.bicolor Z.mays Z.mays O.sativa O.sativa B.distachyon B.distachyon A.lyrata A.lyrata A.thaliana A.thaliana L.japonicus L.japonicus M.truncatula M.truncatula V.vinifera V.vinifera P.trichocarpa P.trichocarpa R.communis R.communis T.trahens T.trahens D.discoideum D.discoideum 4: Spastic paraplegia|| A.macrogynus A.macrogynus S.punctatus S.punctatus M.globosa M.globosa U.maydis U.maydis C.neoformans C.neoformans P.chrysosporium P.chrysosporium S.commune S.commune C.cinerea C.cinerea L.bicolor L.bicolor S.pombe S.pombe B.fuckeliana B.fuckeliana S.sclerotiorum S.sclerotiorum F.graminearum F.graminearum M.grisea M.grisea 5: Bileacid synthesisdefect || N.crassa N.crassa P.anserina P.anserina P.chrysogenum P.chrysogenum A.clavatus A.clavatus A.fumigatus A.fumigatus N.fischeri N.fischeri A.flavus A.flavus A.oryzae A.oryzae A.niger A.niger A.nidulans Fungi A.nidulans U.reesii U.reesii C.immitis C.immitis C.posadasii C.posadasii P.nodorum P.nodorum T.melanosporum T.melanosporum Y.lipolytica Y.lipolytica 6: Adrenal hyperplasia P.pastoris P.pastoris C.lusitaniae C.lusitaniae D.hansenii D.hansenii M.guilliermondii M.guilliermondii S.stipitis S.stipitis L.elongisporus L.elongisporus C.tropicalis C.tropicalis C.albicans C.albicans C.dubliniensis C.dubliniensis K.lactis K.lactis PRESENCE A.gossypii A.gossypii K.waltii K.waltii L.thermotolerans L.thermotolerans GAIN Z.rouxii Z.rouxii V.polyspora V.polyspora C.glabrata C.glabrata S.bayanus S.bayanus S.mikatae S.mikatae S.cerevisiae S.cerevisiae S.paradoxus S.paradoxus S.arctica S.arctica C.owczarzaki C.owczarzaki M.brevicollis M.brevicollis S.rosetta S.rosetta S.mansoni S.mansoni ABSENCE B.malayi B.malayi C.briggsae C.briggsae LOSS C.elegans C.elegans D.pulex D.pulex A.pisum A.pisum P.humanus P.humanus A.mellifera A.mellifera N.vitripennis N.vitripennis B.mori B.mori T.castaneum T.castaneum D.melanogaster D.melanogaster D.pseudoobscura D.pseudoobscura A.gambiae A.gambiae A.aegypti A.aegypti C.quinquefasciatus Metazoa C.quinquefasciatus B.floridae B.floridae T.adhaerens T.adhaerens 0 Log-likelihood RatioScale S.purpuratus S.purpuratus H.magnipapillata H.magnipapillata 10 N.vectensis N.vectensis C.intestinalis C.intestinalis D.rerio D.rerio 20 O.latipes O.latipes F.rubripes F.rubripes 30 T.nigroviridis T.nigroviridis X.tropicalis X.tropicalis 40 G.gallus G.gallus M.gallopavo M.gallopavo O.anatinus O.anatinus 50 M.domestica M.domestica S.scrofa S.scrofa 60 M.musculus M.musculus C.familiaris C.familiaris B.taurus B.taurus H.sapiens H.sapiens LLR 31.2 31.2 31.2 31.2 31.2 31.2 31.2 31.2 31.2 31.2 31.2 31.2 31.2 31.2 31.2 31.2 31.2 31.2 31.2 31.2 31.2 31.2 31.3 31.4 32.2 33.7 33.8 33.8 33.8 33.8 33.8 33.8 33.8 Notes 6 6 4 /5 3 2 1 1 PG K H L K J J G H I H G F F F F C C C C C C C C C C C C C C C C C C C Protein CYP21A1P CYP21A1P CYP51A1 CYP27A1 CYP19A1 CYP11B2 CYP4A11 CYP27B1 CYP4F11 CYP4F22 C12orf65 DHTKD1 CYB5R2 ADSSL1 CYP2A6 CYP3A4 CYP4B1 CYP2U1 CYP2F1 CYP4Z1 CYP4F8 CYP4F3 CYP4F2 ACOXL MTRF1 OGDH IREB2 ADSS ACO1 PDHX ACO2 FMO4 FMO2 FMO5 FMO1 1: Ichthyosis || Num ofECMGenes:2.Predicted100.Strength:2.5 ECM 1,Geneset"D-2-hydroxyglutaricaciduria",Page2 Prokaryotes Prokaryotes Last CommonAncestor E.cuniculi E.cuniculi E.histolytica E.histolytica E.dispar E.dispar G.lamblia G.lamblia T.vaginalis T.vaginalis T.brucei T.brucei T.cruzi T.cruzi
Load more

Recommended publications
  • CYP26C1 Is a Hydroxylase of Multiple Active Retinoids and Interacts with Cellular Retinoic Acid Binding Proteins S
    Supplemental material to this article can be found at: http://molpharm.aspetjournals.org/content/suppl/2018/02/23/mol.117.111039.DC1 1521-0111/93/5/489–503$35.00 https://doi.org/10.1124/mol.117.111039 MOLECULAR PHARMACOLOGY Mol Pharmacol 93:489–503, May 2018 Copyright ª 2018 by The American Society for Pharmacology and Experimental Therapeutics CYP26C1 Is a Hydroxylase of Multiple Active Retinoids and Interacts with Cellular Retinoic Acid Binding Proteins s Guo Zhong, David Ortiz, Alex Zelter, Abhinav Nath, and Nina Isoherranen Departments of Pharmaceutics (G.Z., N.I.) and Medicinal Chemistry (D.O., A.N.), School of Pharmacy, and Department of Biochemistry, School of Medicine (A.Z.), University of Washington, Seattle, Washington Received October 31, 2017; accepted February 22, 2018 ABSTRACT Downloaded from The clearance of retinoic acid (RA) and its metabolites is believed orientation of retinoids within the CYP26C1 active site. In compar- to be regulated by the CYP26 enzymes, but the specific roles of ison with other CYP26 family members, CYP26C1 was up to CYP26A1, CYP26B1, and CYP26C1 in clearing active vitamin A 10-fold more efficient in clearing 4-oxo-atRA (intrinsic clearance metabolites have not been defined. The goal of this study was to 153 ml/min/pmol) than CYP26A1 and CYP26B1, suggesting that establish the substrate specificity of CYP26C1, and determine CYP26C1 may be important in clearing this active retinoid. In whether CYP26C1 interacts with cellular retinoic acid binding support of this, CRABPs delivered 4-oxo-atRA and atRA for proteins (CRABPs). CYP26C1 was found to effectively metabo- metabolism by CYP26C1.
    [Show full text]
  • Impaired Hepatic Drug and Steroid Metabolism in Congenital Adrenal
    European Journal of Endocrinology (2010) 163 919–924 ISSN 0804-4643 CLINICAL STUDY Impaired hepatic drug and steroid metabolism in congenital adrenal hyperplasia due to P450 oxidoreductase deficiency Dorota Tomalik-Scharte1, Dominique Maiter2, Julia Kirchheiner3, Hannah E Ivison, Uwe Fuhr1 and Wiebke Arlt School of Clinical and Experimental Medicine, Centre for Endocrinology, Diabetes and Metabolism (CEDAM), University of Birmingham, Birmingham B15 2TT, UK, 1Department of Pharmacology, University Hospital, University of Cologne, 50931 Cologne, Germany, 2Department of Endocrinology, University Hospital Saint Luc, 1200 Brussels, Belgium and 3Department of Pharmacology of Natural Products and Clinical Pharmacology, University of Ulm, 89019 Ulm, Germany (Correspondence should be addressed to W Arlt; Email: [email protected]) Abstract Objective: Patients with congenital adrenal hyperplasia due to P450 oxidoreductase (POR) deficiency (ORD) present with disordered sex development and glucocorticoid deficiency. This is due to disruption of electron transfer from mutant POR to microsomal cytochrome P450 (CYP) enzymes that play a key role in glucocorticoid and sex steroid synthesis. POR also transfers electrons to all major drug- metabolizing CYP enzymes, including CYP3A4 that inactivates glucocorticoid and oestrogens. However, whether ORD results in impairment of in vivo drug metabolism has never been studied. Design: We studied an adult patient with ORD due to homozygous POR A287P, the most frequent POR mutation in Caucasians, and her clinically unaffected, heterozygous mother. The patient had received standard dose oestrogen replacement from 17 until 37 years of age when it was stopped after she developed breast cancer. Methods: Both subjects underwent in vivo cocktail phenotyping comprising the oral administration of caffeine, tolbutamide, omeprazole, dextromethorphan hydrobromide and midazolam to assess the five major drug-metabolizing CYP enzymes.
    [Show full text]
  • Identification and Developmental Expression of the Full Complement Of
    Goldstone et al. BMC Genomics 2010, 11:643 http://www.biomedcentral.com/1471-2164/11/643 RESEARCH ARTICLE Open Access Identification and developmental expression of the full complement of Cytochrome P450 genes in Zebrafish Jared V Goldstone1, Andrew G McArthur2, Akira Kubota1, Juliano Zanette1,3, Thiago Parente1,4, Maria E Jönsson1,5, David R Nelson6, John J Stegeman1* Abstract Background: Increasing use of zebrafish in drug discovery and mechanistic toxicology demands knowledge of cytochrome P450 (CYP) gene regulation and function. CYP enzymes catalyze oxidative transformation leading to activation or inactivation of many endogenous and exogenous chemicals, with consequences for normal physiology and disease processes. Many CYPs potentially have roles in developmental specification, and many chemicals that cause developmental abnormalities are substrates for CYPs. Here we identify and annotate the full suite of CYP genes in zebrafish, compare these to the human CYP gene complement, and determine the expression of CYP genes during normal development. Results: Zebrafish have a total of 94 CYP genes, distributed among 18 gene families found also in mammals. There are 32 genes in CYP families 5 to 51, most of which are direct orthologs of human CYPs that are involved in endogenous functions including synthesis or inactivation of regulatory molecules. The high degree of sequence similarity suggests conservation of enzyme activities for these CYPs, confirmed in reports for some steroidogenic enzymes (e.g. CYP19, aromatase; CYP11A, P450scc; CYP17, steroid 17a-hydroxylase), and the CYP26 retinoic acid hydroxylases. Complexity is much greater in gene families 1, 2, and 3, which include CYPs prominent in metabolism of drugs and pollutants, as well as of endogenous substrates.
    [Show full text]
  • Synonymous Single Nucleotide Polymorphisms in Human Cytochrome
    DMD Fast Forward. Published on February 9, 2009 as doi:10.1124/dmd.108.026047 DMD #26047 TITLE PAGE: A BIOINFORMATICS APPROACH FOR THE PHENOTYPE PREDICTION OF NON- SYNONYMOUS SINGLE NUCLEOTIDE POLYMORPHISMS IN HUMAN CYTOCHROME P450S LIN-LIN WANG, YONG LI, SHU-FENG ZHOU Department of Nutrition and Food Hygiene, School of Public Health, Peking University, Beijing 100191, P. R. China (LL Wang & Y Li) Discipline of Chinese Medicine, School of Health Sciences, RMIT University, Bundoora, Victoria 3083, Australia (LL Wang & SF Zhou). 1 Copyright 2009 by the American Society for Pharmacology and Experimental Therapeutics. DMD #26047 RUNNING TITLE PAGE: a) Running title: Prediction of phenotype of human CYPs. b) Author for correspondence: A/Prof. Shu-Feng Zhou, MD, PhD Discipline of Chinese Medicine, School of Health Sciences, RMIT University, WHO Collaborating Center for Traditional Medicine, Bundoora, Victoria 3083, Australia. Tel: + 61 3 9925 7794; fax: +61 3 9925 7178. Email: [email protected] c) Number of text pages: 21 Number of tables: 10 Number of figures: 2 Number of references: 40 Number of words in Abstract: 249 Number of words in Introduction: 749 Number of words in Discussion: 1459 d) Non-standard abbreviations: CYP, cytochrome P450; nsSNP, non-synonymous single nucleotide polymorphism. 2 DMD #26047 ABSTRACT Non-synonymous single nucleotide polymorphisms (nsSNPs) in coding regions that can lead to amino acid changes may cause alteration of protein function and account for susceptivity to disease. Identification of deleterious nsSNPs from tolerant nsSNPs is important for characterizing the genetic basis of human disease, assessing individual susceptibility to disease, understanding the pathogenesis of disease, identifying molecular targets for drug treatment and conducting individualized pharmacotherapy.
    [Show full text]
  • Hepatic Gene Expression of Bile Acid Synthesis Genes from Wild-Type and Fxr−/− Mice
    A 2.0 Acox2 B 2.0 Akr1c14 C 2.0 Akr1d1 D 2.0 Amacr ** 1.5 1.5 1.5 1.5 1.0 1.0 1.0 1.0 0.5 0.5 0.5 0.5 mRNA (Fold Change) mRNA mRNA (Fold Change) mRNA mRNA (Fold Change) mRNA mRNA (Fold Change) mRNA 0.0 0.0 0.0 0.0 GSK − 30’ 1h 2h − 30’ 1h 2h GSK − 30’ 1h 2h − 30’ 1h 2h GSK − 30’ 1h 2h − 30’ 1h 2h GSK − 30’ 1h 2h − 30’ 1h 2h FXR WT Fxr−/− FXR WT Fxr−/− FXR WT Fxr−/− FXR WT Fxr−/− E F 2.0 Cyp7b1 2.0 Cyp27a1 G 2.0 Cyp39a1 H 2.0 Hsd3b7 1.5 1.5 1.5 1.5 * 1.0 1.0 1.0 1.0 0.5 0.5 0.5 0.5 mRNA (Fold Change) mRNA mRNA (Fold Change) mRNA mRNA (Fold Change) mRNA mRNA (Fold Change) mRNA 0.0 0.0 0.0 0.0 GSK − 30’ 1h 2h − 30’ 1h 2h GSK − 30’ 1h 2h − 30’ 1h 2h GSK − 30’ 1h 2h − 30’ 1h 2h GSK − 30’ 1h 2h − 30’ 1h 2h FXR WT Fxr−/− FXR WT Fxr−/− FXR WT Fxr−/− FXR WT Fxr−/− I J K 2.0 Hsd17b4 2.0 Scp2 2.0 Slc27a5 L Fxr Cyp7a1 Cyp8b1 1.0 1.5 1.5 1.5 * 1.0 1.0 1.0 0.5 *** *** 0.5 0.5 0.5 mRNA (Fold Change) mRNA mRNA (Fold Change) mRNA mRNA (Fold Change) mRNA mRNA (Fold Change) mRNA *** *** *** 0.0 0.0 0.0 0.0 *** GSK − 30’ 1h 2h − 30’ 1h 2h GSK − 30’ 1h 2h − 30’ 1h 2h GSK − 30’ 1h 2h − 30’ 1h 2h Time (h) 0 4 16 0 4 16 0 4 16 FXR WT Fxr−/− FXR WT Fxr−/− FXR WT Fxr−/− post plating M N CYP7A1 CYP8B1 Supplementary Figure 1 – FXR activation leads to rapid changes in gene expression 1.0 1.0 (A-K) Hepatic gene expression of bile acid synthesis genes from wild-type and Fxr−/− mice.
    [Show full text]
  • TRANSLATIONALLY by AMPK a Dissertation
    CHOLESTEROL 7 ALPHA-HYDROXYLASE IS REGULATED POST- TRANSLATIONALLY BY AMPK A dissertation submitted to Kent State University in partial fulfillment of the requirements for the Degree of Doctor of Philosophy By Mauris E.C. Nnamani May 2009 Dissertation written by Mauris E. C. Nnamani B.S, Kent State University, 2006 Ph.D., Kent State University, 2009 Approved by Diane Stroup Advisor Gail Fraizer Members, Doctoral Dissertation Committee S. Vijayaraghavan Arne Gericke Jennifer Marcinkiewicz Accepted by Robert Dorman , Director, School of Biomedical Science John Stalvey , Dean, Collage of Arts and Sciences ii TABLE OF CONTENTS LIST OF FIGURES……………………………………………………………..vi ACKNOWLEDGMENTS……………………………………………………..viii CHAPTER I: INTRODUCTION……………………………………….…........1 a. Bile Acid Synthesis…………………………………………….……….2 i. Importance of Bile Acid Synthesis Pathway………………….….....2 ii. Bile Acid Transport..…………………………………...…...………...3 iii. Bile Acid Synthesis Pathway………………………………………...…4 iv. Classical Bile Acid Synthesis Pathway…..……………………..…..8 Cholesterol 7 -hydroxylase (CYP7A1)……..........………….....8 Transcriptional Regulation of Cholesterol 7 -hydroxylase by Bile Acid-activated FXR…………………………….....…10 CYP7A1 Transcriptional Repression by SHP-dependant Mechanism…………………………………………………...10 CYP7A1 Transcriptional Repression by SHP-independent Mechanism……………………………………..…………….…….11 CYP7A1 Transcriptional Repression by Activated Cellular Kinase…….…………………………...…………………….……12 v. Alternative/ Acidic Bile Acid Synthesis Pathway…………......…….12 Sterol 27-hydroxylase (CYP27A1)……………….…………….12
    [Show full text]
  • Catalytic Activities of Tumor-Specific Human Cytochrome P450 CYP2W1 Toward Endogenous Substrates S
    Supplemental material to this article can be found at: http://dmd.aspetjournals.org/content/suppl/2016/03/02/dmd.116.069633.DC1 1521-009X/44/5/771–780$25.00 http://dx.doi.org/10.1124/dmd.116.069633 DRUG METABOLISM AND DISPOSITION Drug Metab Dispos 44:771–780, May 2016 Copyright ª 2016 by The American Society for Pharmacology and Experimental Therapeutics Catalytic Activities of Tumor-Specific Human Cytochrome P450 CYP2W1 Toward Endogenous Substrates s Yan Zhao, Debin Wan, Jun Yang, Bruce D. Hammock, and Paul R. Ortiz de Montellano Department of Pharmaceutical Chemistry, University of California, San Francisco (Y.Z., P.R.O.M.) and Department of Entomology and Cancer Center, University of California, Davis, CA (D.W., J.Y., B.D.H.) Received January 25, 2015; accepted February 29, 2016 ABSTRACT CYP2W1 is a recently discovered human cytochrome P450 enzyme 4-OH all-trans retinol, and it also oxidizes retinal. The enzyme much with a distinctive tumor-specific expression pattern. We show here less efficiently oxidizes 17b-estradiol to 2-hydroxy-(17b)-estradiol and that CYP2W1 exhibits tight binding affinities for retinoids, which have farnesol to a monohydroxylated product; arachidonic acid is, at best, Downloaded from low nanomolar binding constants, and much poorer binding constants a negligible substrate. These findings indicate that CYP2W1 probably in the micromolar range for four other ligands. CYP2W1 converts all- plays an important role in localized retinoid metabolism that may be trans retinoic acid (atRA) to 4-hydroxy atRA and all-trans retinol to intimately linked to its involvement in tumor development.
    [Show full text]
  • Impaired Hepatic Drug and Steroid Metabolism in Congenital Adrenal
    European Journal of Endocrinology (2010) 163 919–924 ISSN 0804-4643 CLINICAL STUDY Impaired hepatic drug and steroid metabolism in congenital adrenal hyperplasia due to P450 oxidoreductase deficiency Dorota Tomalik-Scharte1, Dominique Maiter2, Julia Kirchheiner3, Hannah E Ivison, Uwe Fuhr1 and Wiebke Arlt School of Clinical and Experimental Medicine, Centre for Endocrinology, Diabetes and Metabolism (CEDAM), University of Birmingham, Birmingham B15 2TT, UK, 1Department of Pharmacology, University Hospital, University of Cologne, 50931 Cologne, Germany, 2Department of Endocrinology, University Hospital Saint Luc, 1200 Brussels, Belgium and 3Department of Pharmacology of Natural Products and Clinical Pharmacology, University of Ulm, 89019 Ulm, Germany (Correspondence should be addressed to W Arlt; Email: [email protected]) Abstract Objective: Patients with congenital adrenal hyperplasia due to P450 oxidoreductase (POR) deficiency (ORD) present with disordered sex development and glucocorticoid deficiency. This is due to disruption of electron transfer from mutant POR to microsomal cytochrome P450 (CYP) enzymes that play a key role in glucocorticoid and sex steroid synthesis. POR also transfers electrons to all major drug- metabolizing CYP enzymes, including CYP3A4 that inactivates glucocorticoid and oestrogens. However, whether ORD results in impairment of in vivo drug metabolism has never been studied. Design: We studied an adult patient with ORD due to homozygous POR A287P, the most frequent POR mutation in Caucasians, and her clinically unaffected, heterozygous mother. The patient had received standard dose oestrogen replacement from 17 until 37 years of age when it was stopped after she developed breast cancer. Methods: Both subjects underwent in vivo cocktail phenotyping comprising the oral administration of caffeine, tolbutamide, omeprazole, dextromethorphan hydrobromide and midazolam to assess the five major drug-metabolizing CYP enzymes.
    [Show full text]
  • Glenville Jones Nationality
    -1- Updated: 9 February 2018 CURRICULUM VITAE Name: Glenville Jones Nationality: British/Canadian Citizen Mailing Address: Department of Biochemistry 6th Floor, Botterell Hall Queen's University Kingston, Ontario, Canada K7L 3N6 EDUCATION B.Sc. Degree 1967, Liverpool University (Chemistry, General Biology) B.Sc. (Honours) 1968, Liverpool University (Biochemistry) Ph.D. Degree 1971, Liverpool University (Biochemistry), with Dr George A.J. Pitt Postdoctoral Training University of Calgary, Alberta, Canada (With Dr. John N. Hawthorne) (Oct. 1971-Oct. 1975) University of Wisconsin, Madison, U.S.A. (With Dr. Hector F. DeLuca) CURRENT POSITIONS HELD June 1 2011-Present Craine Professor of Biochemistry, Department of Biomedical & Molecular Sciences; Professor, Department of Medicine, Queen’s University, Kingston, Ontario, Canada July 2002-Present Scientific Advisory Board, Cytochroma/OPKO Renal, Miami, Florida, US Sept 2017-Present Chair of Advisory Committee, Vitamin D External Quality Assurance Scheme (DEQAS) PAST POSITIONS HELD Nov. 1975 - Feb. 1984 Assistant Professor (1975-1982) & Associate Professor (1982-1984), Division of Endocrinology Research, Research Institute, The Hospital for Sick Children, Toronto, ON, Canada Assistant Professor (1975-1983) & Associate Professor (1983-1984), Depts. Biochemistry, Pediatrics & School of Graduate Studies, University of Toronto, Toronto, ON, Canada Feb. 1984 - June 1988 Associate Professor, Depts of Medicine & Biochemistry, Queen's University, Kingston, ON, July 1988 – June 2002 Professor of Biochemistry
    [Show full text]
  • Robert Foti to Cite This Version
    Characterization of xenobiotic substrates and inhibitors of CYP26A1, CYP26B1 and CYP26C1 using computational modeling and in vitro analyses Robert Foti To cite this version: Robert Foti. Characterization of xenobiotic substrates and inhibitors of CYP26A1, CYP26B1 and CYP26C1 using computational modeling and in vitro analyses. Agricultural sciences. Université Nice Sophia Antipolis, 2016. English. NNT : 2016NICE4033. tel-01376678 HAL Id: tel-01376678 https://tel.archives-ouvertes.fr/tel-01376678 Submitted on 5 Oct 2016 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Université de Nice-Sophia Antipolis Thèse pour obtenir le grade de DOCTEUR DE L’UNIVERSITE NICE SOPHIA ANTIPOLIS Spécialité : Interactions Moléculaires et Cellulaires Ecole Doctorale : Sciences de la Vie et de la Santé (SVS) Caractérisation des substrats xénobiotiques et des inhibiteurs des cytochromes CYP26A1, CYP26B1 et CYP26C1 par modélisation moléculaire et études in vitro présentée et soutenue publiquement par Robert S. Foti Le 4 Juillet 2016 Membres du jury Dr. Danièle Werck-Reichhart Rapporteur Dr. Philippe Roche Rapporteur Pr. Serge Antonczak Examinateur Dr. Philippe Breton Examinateur Pr. Philippe Diaz Examinateur Dr. Dominique Douguet Directrice de thèse 1 1. Table of Contents 1. Table of Contents ..............................................................................................................................
    [Show full text]
  • Metabolic Activation and Toxicological Evaluation of Polychlorinated Biphenyls in Drosophila Melanogaster T
    www.nature.com/scientificreports OPEN Metabolic activation and toxicological evaluation of polychlorinated biphenyls in Drosophila melanogaster T. Idda1,7, C. Bonas1,7, J. Hofmann1, J. Bertram1, N. Quinete1,2, T. Schettgen1, K. Fietkau3, A. Esser1, M. B. Stope4, M. M. Leijs3, J. M. Baron3, T. Kraus1, A. Voigt5,6 & P. Ziegler1* Degradation of polychlorinated biphenyls (PCBs) is initiated by cytochrome P450 (CYP) enzymes and includes PCB oxidation to OH-metabolites, which often display a higher toxicity than their parental compounds. In search of an animal model refecting PCB metabolism and toxicity, we tested Drosophila melanogaster, a well-known model system for genetics and human disease. Feeding Drosophila with lower chlorinated (LC) PCB congeners 28, 52 or 101 resulted in the detection of a human-like pattern of respective OH-metabolites in fy lysates. Feeding fies high PCB 28 concentrations caused lethality. Thus we silenced selected CYPs via RNA interference and analyzed the efect on PCB 28-derived metabolite formation by assaying 3-OH-2′,4,4′-trichlorobiphenyl (3-OHCB 28) and 3′-OH-4′,4,6′-trichlorobiphenyl (3′-OHCB 28) in fy lysates. We identifed several drosophila CYPs (dCYPs) whose knockdown reduced PCB 28-derived OH-metabolites and suppressed PCB 28 induced lethality including dCYP1A2. Following in vitro analysis using a liver-like CYP-cocktail, containing human orthologues of dCYP1A2, we confrm human CYP1A2 as a PCB 28 metabolizing enzyme. PCB 28-induced mortality in fies was accompanied by locomotor impairment, a common phenotype of neurodegenerative disorders. Along this line, we show PCB 28-initiated caspase activation in diferentiated fy neurons.
    [Show full text]
  • Vitamin D Receptor (VDR) and Cholesterol Homeostasis: Interplay of VDR Enzyme Targets and Vitamin D Deficiency
    Vitamin D Receptor (VDR) and Cholesterol Homeostasis: Interplay of VDR Enzyme Targets and Vitamin D Deficiency by Holly P. Quach A thesis submitted in conformity with the requirements for the degree of Doctor of Philosophy Department of Pharmaceutical Sciences University of Toronto © Copyright by Holly P. Quach, 2016 Vitamin D Receptor (VDR) and Cholesterol Homeostasis: Interplay of VDR Enzyme Targets and Vitamin D Deficiency Holly P. Quach Doctor of Philosophy Department of Pharmaceutical Sciences University of Toronto 2016 Abstract Vitamin D deficiency is speculated to play a role in hypercholesterolemia. However, there has been little molecular evidence to link the two until recent evidence identified the vitamin D receptor (VDR) and its natural ligand, 1α,25-dihydroxyvitamin D3 [1,25(OH)2D3], as key regulators of cholesterol metabolism. In the liver, 1,25(OH)2D3-liganded VDR directly inhibited the small heterodimer partner (Shp) to increase expression of cholesterol 7α-hydroxylase (Cyp7a1), the rate-limiting enzyme for cholesterol metabolism to bile acids, a mechanism independent of the farnesoid X receptor. Vitamin D deficiency was established in mice after 8 weeks of the D-deficient diet, which resulted in decreased levels of plasma and liver 1,25(OH)2D3, downregulation of hepatic Vdr and Cyp7a1, and elevation of Shp. Consequently, higher plasma and liver cholesterol levels were observed. Intervention with 1,25(OH)2D3 or vitamin D3 reversed the altered expression of these cholesterol-regulating genes and lowered cholesterol levels back to baseline levels. The correlations between liver cholesterol vs. liver 1,25(OH)2D3 and Cyp7a1 expression in mice were also found in human liver tissue, suggesting that the VDR could be a ii potential therapeutic target for cholesterol lowering.
    [Show full text]